PIK3CA and triple-negative breast carcinoma: Therefore, we believe that a more complete inhibition of the PI3K and TORC1/2 pathway will increase HRD more than mTOR inhibition alone, sensitizing triple negative breast cancers to DNA damaging cisplatin and immune checkpoint inhibitors.